Delivery Order SPE2DB22D2007-SPE2DB25FJ3RJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,102.87 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg–195 mg capsules (100 count) on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Rytary ER 23.75 mg-95 mg capsules in a quantity of 100 units. This is a firm fixed-price delivery order with a ceiling value of $1,861.95, with an ultimate completion date of September 5, 2025. The contract was not set-aside and represents a competitive award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $6,559.33 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of RYTARY ER 36.25 mg–145 mg capsules (100-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $3,565.50 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RYTARY ER (extended-release carbidopa-levodopa) 36.25 mg-145 mg capsules in a quantity of 100 units. The delivery order is issued under a firm fixed-price contract with an ultimate completion date of July 21, 2025, and will be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This award includes no set-aside designation and was awarded...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,025.48 on August 5, 2025, for the supply of Rytary ER 48.75 mg-195 mg capsules (100-count). The contract, which is non-set-aside and competitively awarded, utilizes firm fixed pricing and is scheduled for completion by August 6, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's larger...
- The Defense Logistics Agency awarded a $6,963.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Rytary ER 48.75 mg-195 mg capsules (100-count containers). This is a non-set-aside competitive award with an ultimate completion date of August 1, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Rytary is a combination levodopa/carbidopa extended-release medication used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $13,679.70 to AmerisourceBergen Drug Corp for the supply of Rytary ER 36.25 mg-145 mg capsules (100 count) under a firm fixed price contract. This competitive award, issued on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $44,283.84 to AmerisourceBergen Drug Corp for the supply of RYTARY ER (extended-release carbidopa-levodopa) 36.25 mg-145 mg capsules in a quantity of 100 units. The contract is a firm fixed price delivery order with an ultimate completion date of June 9, 2025, and was awarded on June 6, 2025 without any set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $5,271.41 delivery order to AmerisourceBergen Drug Corp on July 7, 2025, for the supply of Rytary ER 23.75 mg-95 mg capsules (100-count units). The contract was competitively awarded without set-aside designation and carries a firm fixed price structure with an ultimate completion date of July 8, 2025. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $6,241.31 to AmerisourceBergen Drug Corp for Rytary ER 36.25 mg–145 mg capsules (100-count supply) on June 5, 2025, with completion scheduled for June 6, 2025. This non-set-aside, firm fixed-price delivery order represents pharmaceutical procurement for military healthcare support. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical procurement and holds...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3RJDelivery Order
The Defense Logistics Agency awarded a $4,741.86 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for Rytary ER 48.75 mg-195 mg capsules (100-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 6, 2025. The contract is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, and represents a child delivery order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor for the Defense Logistics Agency's medical supply chain. Rytary (carbidopa-levodopa) is a neurological medication used in Parkinson's disease treatment, reflecting the company's portfolio of specialty pharmaceuticals serving military healthcare systems. The award is issued under AmerisourceBergen's $999.999 billion Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026 and enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/5/25 |